Literature DB >> 7059472

The Tennessee antigen test. An evaluation in cancer and non-cancer patients and normal subjects.

C R Pentycross.   

Abstract

The Tennagen test has been evaluated in "normal" subjects, patients with cancer (predominantly colorectal) and patients with non-malignant disease. The incidence of positive values was found to be higher in patients with clinically active cancer than in those with benign conditions or normal subjects. In our hands the test fell far short of the 90% reliability previously claimed. This may be partly due to an underestimate of the upper normal limit in earlier studies. A small series of follow-up studies after resection for colorectal cancer have so far failed to reveal any advantage to be gained by Tennagen tests over existing methods, but these studied will be continued.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059472      PMCID: PMC2010906          DOI: 10.1038/bjc.1982.37

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  3 in total

1.  Proceedings: Intermolecular heterogeneity of the carcinoembryonic antigen.

Authors:  C Banjo; J Shuster; P Gold
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

2.  Radioimmunoassay methods for carcinoembryonic antigen.

Authors:  F Searle; A C Lovesey; B A Roberts; G I Rogers; K D Bagshawe
Journal:  J Immunol Methods       Date:  1974-03       Impact factor: 2.303

3.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

  3 in total
  3 in total

1.  Determination of TPA levels in breast cancer and controls.

Authors:  K Mross; B Mross; D I Wolfrum; H Rauschecker
Journal:  Klin Wochenschr       Date:  1983-05-02

2.  Simultaneous determination of six tumor markers in patients with prostatic carcinoma and bladder tumors.

Authors:  B Schwemmer; W Schütz; R M Kuntz; A Lehmer
Journal:  Urol Res       Date:  1985

3.  Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1983-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.